{"id":133882,"date":"2026-06-29T12:13:17","date_gmt":"2026-06-29T06:43:17","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=133882"},"modified":"2026-06-29T12:13:19","modified_gmt":"2026-06-29T06:43:19","slug":"dr-reddys-share-price-rise-6th-day-new-52w-high","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/","title":{"rendered":"Dr Reddy&#8217;s Laboratories Shares Extend Rise to 6th Consecutive Day, Hitting New 52-Week High on High Volumes"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>DRREDDY Rs 1,406.80 (+4.17%). New 52W High Rs 1,414.90 today. 52W Low Rs 1,148.40. Vol 4M+ shares. 6th consecutive gain. Nifty Pharma +1.73%. USFDA Form 483 &#8211; 7 obs, Bachupally.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/stocks\/drreddy\/dr-reddy%27s-laboratories-ltd-share-price-today\">Dr Reddy&#8217;s Laboratories<\/a> share price has advanced for the sixth consecutive trading session, gaining 4.17% to Rs 1,406.80 and touching a new intraday 52-week high of Rs 1,414.90 in today&#8217;s session. Trading volumes have surged past 4 million shares, well above the stock&#8217;s daily average, signalling institutional accumulation behind the move. The six-session winning streak has coincided with a broad-based rally in the Nifty Pharma index, which is the top performing sector today at +1.73%, providing powerful sectoral tailwinds to Dr Reddy&#8217;s share price.<\/p>\n<p>The breakout above the previous 52-week high of Rs 1,375.90 is a technically significant event that chartists typically view as a continuation signal. The move comes against a backdrop of positive news flow including product launches in semaglutide, biosimilar pipeline progress and a Nomura Buy rating with a target of Rs 1,740. The USFDA recently issued a Form 483 with seven observations at the company&#8217;s Bachupally biologics facility after a Pre-License Inspection, but investors are treating the development as a standard regulatory checkpoint rather than a material risk, given the company&#8217;s track record of resolving similar observations.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=drreddy-6day\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#Dr_Reddys_Share_Price_Live_Trading_Data\" title=\"Dr Reddy&#8217;s Share Price: Live Trading Data\">Dr Reddy&#8217;s Share Price: Live Trading Data<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#Why_Dr_Reddys_Share_Price_Is_Rising_for_6_Consecutive_Days\" title=\"Why Dr Reddy&#8217;s Share Price Is Rising for 6 Consecutive Days\">Why Dr Reddy&#8217;s Share Price Is Rising for 6 Consecutive Days<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#Dr_Reddys_USFDA_Form_483_Seven_Observations_Explained\" title=\"Dr Reddy&#8217;s USFDA Form 483: Seven Observations Explained\">Dr Reddy&#8217;s USFDA Form 483: Seven Observations Explained<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#What_Investors_Should_Watch_Next\" title=\"What Investors Should Watch Next\">What Investors Should Watch Next<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#Why_is_Dr_Reddys_share_price_rising_for_6_consecutive_days\" title=\"Why is Dr Reddy&#8217;s share price rising for 6 consecutive days?\">Why is Dr Reddy&#8217;s share price rising for 6 consecutive days?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#What_is_the_USFDA_Form_483_with_seven_observations_for_Dr_Reddys\" title=\"What is the USFDA Form 483 with seven observations for Dr Reddy&#8217;s?\">What is the USFDA Form 483 with seven observations for Dr Reddy&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#What_is_the_new_52-week_high_for_Dr_Reddys_share_price\" title=\"What is the new 52-week high for Dr Reddy&#8217;s share price?\">What is the new 52-week high for Dr Reddy&#8217;s share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#What_is_Nomuras_target_price_for_Dr_Reddys\" title=\"What is Nomura&#8217;s target price for Dr Reddy&#8217;s?\">What is Nomura&#8217;s target price for Dr Reddy&#8217;s?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#What_products_are_driving_the_Dr_Reddys_share_price_rally\" title=\"What products are driving the Dr Reddy&#8217;s share price rally?\">What products are driving the Dr Reddy&#8217;s share price rally?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/dr-reddys-share-price-rise-6th-day-new-52w-high\/#What_volumes_are_Dr_Reddys_shares_trading_at_today\" title=\"What volumes are Dr Reddy&#8217;s shares trading at today?\">What volumes are Dr Reddy&#8217;s shares trading at today?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_Share_Price_Live_Trading_Data\"><\/span><strong>Dr Reddy&#8217;s Share Price: Live Trading Data<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse;\">\n<tbody>\n<tr style=\"background: #00439D; color: #fff;\">\n<th style=\"padding: 8px 10px; border: 1px solid #CCC; text-align: left;\">Metric<\/th>\n<th style=\"padding: 8px 10px; border: 1px solid #CCC; text-align: left;\">Value<\/th>\n<\/tr>\n<tr style=\"background: #FFF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>CMP (NSE)<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,406.80 (+4.17%, +Rs 56.30)<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Previous Close<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,350.50<\/td>\n<\/tr>\n<tr style=\"background: #FFF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Intraday High (New 52W High)<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,414.90<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Intraday Low<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,355.80<\/td>\n<\/tr>\n<tr style=\"background: #FFF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Previous 52-Week High<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,375.90 (now surpassed)<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>52-Week Low<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,148.40<\/td>\n<\/tr>\n<tr style=\"background: #FFF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Session Volume<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">4 million+ shares (elevated)<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Consecutive Gain Days<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">6th session<\/td>\n<\/tr>\n<tr style=\"background: #FFF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Nifty Pharma Index<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">25,402 (+1.73%) &#8211; top sector today<\/td>\n<\/tr>\n<tr style=\"background: #F5F7FF;\">\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\"><strong>Nomura Target<\/strong><\/td>\n<td style=\"padding: 8px 10px; border: 1px solid #DDD;\">Rs 1,740 (Buy rating)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Dr Reddy&#8217;s Share Price Live on Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Dr_Reddys_Share_Price_Is_Rising_for_6_Consecutive_Days\"><\/span><strong>Why Dr Reddy&#8217;s Share Price Is Rising for 6 Consecutive Days<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Three converging catalysts are behind the Dr Reddy&#8217;s share price six-day rally. First, the Nifty Pharma index has broken above the key 25,000 weekly resistance level and is up 1.73% today, providing a sectoral momentum lift to all pharma heavyweights. The Indian Pharmaceutical Market recorded 12.1% year-on-year growth in May 2026, its sixth consecutive month above 10%, driven by volume, pricing and new product introduction simultaneously. This is a rare trifecta that supports broad-based re-rating for domestic pharma companies.<\/p>\n<p>Second, Dr Reddy&#8217;s has a rich near-term product pipeline. The company became the first to receive Canadian approval for generic semaglutide injection, launched the product in India as Obeda on day one, and has received USFDA acceptance for review of its abatacept biosimilar IV biologics licence application. It also expanded its women&#8217;s health portfolio by acquiring Progynova and Cyclo-Progynova. Nomura recently upgraded its target price to Rs 1,740, reiterating Buy, citing the company&#8217;s strategic shift toward branded generics as a valuation re-rating catalyst.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dr_Reddys_USFDA_Form_483_Seven_Observations_Explained\"><\/span><strong>Dr Reddy&#8217;s USFDA Form 483: Seven Observations Explained<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The USFDA completed a Pre-License Inspection at Dr Reddy&#8217;s biologics manufacturing facility in Bachupally, Hyderabad, between June 16 and June 25, issuing Form 483 with seven observations. A Form 483 is issued when USFDA inspectors identify conditions that may constitute deviations from current Good Manufacturing Practices. It is an initial communication, not a Warning Letter, Import Alert or Complete Response Letter. Companies are given a stipulated timeline to file a corrective action plan. Dr Reddy&#8217;s has confirmed it will address all observations within the required timeframe. A previous Pre-Approval Inspection at the same Bachupally facility in September 2025 had issued five observations, which were resolved without material consequence. Investors are applying the same interpretation to today&#8217;s seven-observation Form 483.<\/p>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to access Dr Reddy&#8217;s live price, analyst research and portfolio tools on Univest.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_Investors_Should_Watch_Next\"><\/span><strong>What Investors Should Watch Next<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Key monitorables for the Dr Reddy&#8217;s share price going forward include the corrective action plan response to the seven USFDA Form 483 observations, the USFDA review timeline for the abatacept biosimilar BLA, semaglutide market reception in India and Canada, and quarterly results guidance on margin and revenue trajectory. With a new 52-week high set today at Rs 1,414.90 and Nomura&#8217;s target at Rs 1,740, the stock still has significant headroom if the company&#8217;s execution remains on track. Technically, sustaining above the previous high of Rs 1,375.90 on any near-term pullback would confirm the breakout. Always consult a SEBI-registered financial advisor before investing.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Dr_Reddys_share_price_rising_for_6_consecutive_days\"><\/span><strong>Why is Dr Reddy&#8217;s share price rising for 6 consecutive days?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#8217;s share price has risen for six consecutive sessions driven by three factors: the Nifty Pharma index rallying on strong domestic IPM growth of 12.1% YoY, positive pipeline catalysts including first-in-Canada semaglutide approval and abatacept biosimilar BLA acceptance by the USFDA, and a Nomura Buy rating with target price of Rs 1,740.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_USFDA_Form_483_with_seven_observations_for_Dr_Reddys\"><\/span><strong>What is the USFDA Form 483 with seven observations for Dr Reddy&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The USFDA completed a Pre-License Inspection at Dr Reddy&#8217;s biologics facility in Bachupally, Hyderabad (June 16-25), and issued Form 483 with seven observations. A Form 483 identifies potential GMP deviations and is not a Warning Letter or Import Alert. Companies have a stipulated timeline to submit corrective action plans. Dr Reddy&#8217;s has confirmed it will address all observations within the required timeframe.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_new_52-week_high_for_Dr_Reddys_share_price\"><\/span><strong>What is the new 52-week high for Dr Reddy&#8217;s share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#8217;s set a new 52-week high of Rs 1,414.90 in today&#8217;s intraday session, surpassing the previous 52-week high of Rs 1,375.90. The current trading price is Rs 1,406.80, up 4.17%. The 52-week low is Rs 1,148.40, representing a 22.5% gain from that low to the current price.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Nomuras_target_price_for_Dr_Reddys\"><\/span><strong>What is Nomura&#8217;s target price for Dr Reddy&#8217;s?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Nomura has a Buy rating on Dr Reddy&#8217;s with a target price of Rs 1,740, implying approximately 23.7% upside from the current price of Rs 1,406.80. Nomura cites the company&#8217;s strategic shift toward branded generics, biosimilar pipeline and women&#8217;s health portfolio expansion as key catalysts for valuation re-rating.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_products_are_driving_the_Dr_Reddys_share_price_rally\"><\/span><strong>What products are driving the Dr Reddy&#8217;s share price rally?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key products supporting the Dr Reddy&#8217;s share price rally include: generic semaglutide injection approved in Canada (first company) and launched in India as Obeda; abatacept biosimilar IV biologics licence application accepted by USFDA for review; women&#8217;s health portfolio expanded with Progynova and Cyclo-Progynova acquisitions; and Bosutinib 400mg launched in the US under first-to-file category.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_volumes_are_Dr_Reddys_shares_trading_at_today\"><\/span><strong>What volumes are Dr Reddy&#8217;s shares trading at today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Dr Reddy&#8217;s is trading on volumes exceeding 4 million shares in today&#8217;s NSE session, significantly above the daily average volume. High volume confirmation of a 52-week high breakout is a technically significant signal that often indicates institutional buying and can sustain directional momentum in the stock.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Why is Dr Reddy's share price rising for 6 consecutive days?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's share price has risen for six consecutive sessions driven by three factors: the Nifty Pharma index rallying on strong domestic IPM growth of 12.1% YoY, positive pipeline catalysts including first-in-Canada semaglutide approval and abatacept biosimilar BLA acceptance by the USFDA, and a Nomura Buy rating with target price of Rs 1,740.\"}},{\"@type\":\"Question\",\"name\":\"What is the USFDA Form 483 with seven observations for Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The USFDA completed a Pre-License Inspection at Dr Reddy's biologics facility in Bachupally, Hyderabad (June 16-25), and issued Form 483 with seven observations. A Form 483 identifies potential GMP deviations and is not a Warning Letter or Import Alert. Companies have a stipulated timeline to submit corrective action plans. Dr Reddy's has confirmed it will address all observations within the required timeframe.\"}},{\"@type\":\"Question\",\"name\":\"What is the new 52-week high for Dr Reddy's share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's set a new 52-week high of Rs 1,414.90 in today's intraday session, surpassing the previous 52-week high of Rs 1,375.90. The current trading price is Rs 1,406.80, up 4.17%. The 52-week low is Rs 1,148.40, representing a 22.5% gain from that low to the current price.\"}},{\"@type\":\"Question\",\"name\":\"What is Nomura's target price for Dr Reddy's?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Nomura has a Buy rating on Dr Reddy's with a target price of Rs 1,740, implying approximately 23.7% upside from the current price of Rs 1,406.80. Nomura cites the company's strategic shift toward branded generics, biosimilar pipeline and women's health portfolio expansion as key catalysts for valuation re-rating.\"}},{\"@type\":\"Question\",\"name\":\"What products are driving the Dr Reddy's share price rally?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key products supporting the Dr Reddy's share price rally include: generic semaglutide injection approved in Canada (first company) and launched in India as Obeda; abatacept biosimilar IV biologics licence application accepted by USFDA for review; women's health portfolio expanded with Progynova and Cyclo-Progynova acquisitions; and Bosutinib 400mg launched in the US under first-to-file category.\"}},{\"@type\":\"Question\",\"name\":\"What volumes are Dr Reddy's shares trading at today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Dr Reddy's is trading on volumes exceeding 4 million shares in today's NSE session, significantly above the daily average volume. High volume confirmation of a 52-week high breakout is a technically significant signal that often indicates institutional buying and can sustain directional momentum in the stock.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dr Reddy&#8217;s Laboratories shares rise for the 6th consecutive session, setting a new 52-week high of Rs 1,414.90 on volumes above 4 million shares. USFDA Form 483, 7 observations at Bachupally biologics facility. Nomura TP Rs 1,740.<\/p>\n","protected":false},"author":34,"featured_media":133917,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[4902],"class_list":["post-133882","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-shares-extend-rise"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1782715421:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["76"],"rank_math_title":["Dr Reddy's Share Price Rise 6th Day: New 52W High on High Volumes"],"rank_math_description":["Dr Reddy's share price extend gains for the 6th consecutive session, hitting a fresh 52-week high of Rs 1,414.90 on volumes above 4 million shares. USFDA 7 Form 483 observations at Bachupally."],"rank_math_focus_keyword":["Dr Reddy's Share Price"],"_wp_old_slug":["dr-reddys-shares-rise-6th-day-new-52w-high"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["133917"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["21923"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Dr-Reddys-Laboratories-Shares-Extend-Rise.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/133882","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/34"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=133882"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/133882\/revisions"}],"predecessor-version":[{"id":133921,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/133882\/revisions\/133921"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/133917"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=133882"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=133882"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=133882"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}